Holger Jensen

2.0k total citations
62 papers, 1.6k citations indexed

About

Holger Jensen is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Holger Jensen has authored 62 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Radiology, Nuclear Medicine and Imaging, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Holger Jensen's work include Radiopharmaceutical Chemistry and Applications (57 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Medical Imaging Techniques and Applications (16 papers). Holger Jensen is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (57 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Medical Imaging Techniques and Applications (16 papers). Holger Jensen collaborates with scholars based in Sweden, Denmark and United States. Holger Jensen's co-authors include Sture Lindegren, Tom Bäck, Stig Palm, Ragnar Hultborn, Lars Jacobsson, Jörgen Elgqvist, Håkan Andersson, Per Albertsson, Emma Aneheim and Elisabet Warnhammar and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer.

In The Last Decade

Holger Jensen

62 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holger Jensen Sweden 23 1.4k 604 346 190 123 62 1.6k
Sture Lindegren Sweden 25 1.7k 1.2× 708 1.2× 413 1.2× 230 1.2× 154 1.3× 79 1.9k
Tom Bäck Sweden 28 1.8k 1.3× 756 1.3× 450 1.3× 308 1.6× 158 1.3× 71 2.0k
Stig Palm Sweden 23 1.6k 1.2× 755 1.3× 431 1.2× 295 1.6× 134 1.1× 53 1.9k
Kwamena E. Baidoo United States 29 1.4k 1.0× 642 1.1× 537 1.6× 99 0.5× 271 2.2× 51 1.8k
Christof Seidl Germany 26 964 0.7× 557 0.9× 399 1.2× 89 0.5× 365 3.0× 59 1.6k
R. Molinet Germany 11 912 0.7× 363 0.6× 226 0.7× 153 0.8× 118 1.0× 14 1.1k
Jörgen Elgqvist Sweden 16 862 0.6× 418 0.7× 199 0.6× 125 0.7× 89 0.7× 27 1.0k
Stephanie Haller Switzerland 19 760 0.5× 359 0.6× 213 0.6× 137 0.7× 87 0.7× 24 1.1k
Robert W. Atcher United States 26 1.6k 1.1× 619 1.0× 455 1.3× 239 1.3× 360 2.9× 64 2.2k
Lars R. Perk Netherlands 17 1.8k 1.3× 600 1.0× 826 2.4× 77 0.4× 481 3.9× 23 2.4k

Countries citing papers authored by Holger Jensen

Since Specialization
Citations

This map shows the geographic impact of Holger Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Jensen more than expected).

Fields of papers citing papers by Holger Jensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Jensen. The network helps show where Holger Jensen may publish in the future.

Co-authorship network of co-authors of Holger Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Jensen. A scholar is included among the top collaborators of Holger Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Jensen. Holger Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jensen, Holger, et al.. (2025). Radiolabeling yield dependency of post-dry distillation decay of astatine-211. Nuclear Medicine and Biology. 144-145. 108999–108999. 1 indexed citations
2.
Herth, Matthias M., Christian B. M. Poulie, Tobias Gustavsson, et al.. (2025). An 211At-labeled Tetrazine for Pretargeted Therapy. Journal of Medicinal Chemistry. 68(4). 4410–4425. 1 indexed citations
3.
Aneheim, Emma, Tom Bäck, Holger Jensen, Stig Palm, & Sture Lindegren. (2024). A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial. PLoS ONE. 19(9). e0307543–e0307543. 2 indexed citations
4.
Battisti, Umberto Maria, et al.. (2024). Rapid Electrophilic 211At‐Astatination of Trimethylgermyl Arenes. ChemPlusChem. 89(9). e202400254–e202400254. 5 indexed citations
5.
Müller, Marius, Sture Lindegren, Emma Aneheim, et al.. (2024). Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer. Journal of Nuclear Medicine. 65(4). 593–599. 12 indexed citations
6.
Jensen, Holger, et al.. (2023). Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211. Pharmaceuticals. 16(4). 595–595. 12 indexed citations
7.
Poulie, Christian B. M., Sture Lindegren, Emma Aneheim, et al.. (2021). Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy. SHILAP Revista de lepidopterología. 2(4). 196–207. 11 indexed citations
8.
Lindegren, Sture, Per Albertsson, Tom Bäck, et al.. (2020). Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. Cancer Biotherapy and Radiopharmaceuticals. 35(6). 425–436. 69 indexed citations
9.
Aneheim, Emma, et al.. (2015). Shelf-Life of ɛ-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugates, Precursors for 211 At Labeling of Antibodies. Cancer Biotherapy and Radiopharmaceuticals. 30(1). 41–45. 6 indexed citations
10.
Bäck, Tom, Tomas Ohlsson, Holger Jensen, et al.. (2014). Sequential Radioimmunotherapy with 177 Lu- and 211 At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. Cancer Biotherapy and Radiopharmaceuticals. 29(6). 238–246. 7 indexed citations
11.
Delle, Ulla, et al.. (2014). Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 765. 48–56. 9 indexed citations
12.
Aneheim, Emma, M.R.St.J. Foreman, Holger Jensen, & Sture Lindegren. (2014). N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides. Applied Radiation and Isotopes. 96. 1–5. 11 indexed citations
13.
Frost, Sofia H.L., Tom Bäck, Nicolas Chouin, et al.. (2012). Comparison of 211 At-PRIT and 211 At-RIT of Ovarian Microtumors in a Nude Mouse Model. Cancer Biotherapy and Radiopharmaceuticals. 28(2). 108–114. 18 indexed citations
14.
Frost, Sofia H.L., Tom Bäck, Nicolas Chouin, et al.. (2011). In Vivo Distribution of Avidin-Conjugated MX35 and 211 At-Labeled, Biotinylated Poly- l -Lysine for Pretargeted Intraperitoneal α-Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals. 26(6). 727–736. 9 indexed citations
15.
Bäck, Tom, Jörgen Elgqvist, Lars Jacobsson, et al.. (2011). Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nuclear Medicine and Biology. 39(1). 15–22. 34 indexed citations
16.
Lindegren, Sture, et al.. (2008). Direct Procedure for the Production of211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate. Journal of Nuclear Medicine. 49(9). 1537–1545. 66 indexed citations
17.
Elgqvist, Jörgen, Peter Bernhardt, Ragnar Hultborn, et al.. (2005). Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.. PubMed. 46(3). 464–71. 43 indexed citations
18.
Orlova, Anna, et al.. (2005). In Vitro Characterization of 211 At-Labeled Antibody A33—a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 514–523. 9 indexed citations
19.
Andersson, Håkan, Jörgen Elgqvist, György Horváth, et al.. (2003). Astatine-211-labeled Antibodies for Treatment of Disseminated Ovarian Cancer. Clinical Cancer Research. 9(10). 3 indexed citations
20.
Lindegren, Sture, Tom Bäck, & Holger Jensen. (2001). Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Applied Radiation and Isotopes. 55(2). 157–160. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sture Lindegren Breakdown of academic impact, for papers by Tom Bäck Breakdown of academic impact, for papers by Stig Palm Breakdown of academic impact, for papers by Kwamena E. Baidoo Breakdown of academic impact, for papers by Christof Seidl Breakdown of academic impact, for papers by R. Molinet Breakdown of academic impact, for papers by Jörgen Elgqvist Breakdown of academic impact, for papers by Stephanie Haller Breakdown of academic impact, for papers by Robert W. Atcher Breakdown of academic impact, for papers by Lars R. Perk
Rankless by CCL
2026